01—Abstract
Summary
Summary of the 10-Q filed May 31, 2022. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported solid financial performance for the three and six months ended April 30, 2022, demonstrating resilience despite global economic headwinds.
Total net revenue grew by 5% and 7% year-over-year for the respective periods, reaching $1.61 billiona and $3.28 billion. This growth was driven by increases across all business segments, particularly Diagnostics and Genomics, which saw a substantial 14% and 15% revenue increase, respectively. While the company experienced a slight revenue impact from the COVID-19 lockdown in Shanghai, affecting its Gas Chromatography production facility, management anticipates this delayed revenue will be recognized in the latter half of fiscal year 2022 and into fiscal year 2023.
Net income also saw a significant improvement, rising to $274 millionb for the quarter and $557 million for the six-month period, up from $216 million and $504 million in the prior year, respectively. Operationally, the company maintained strong gross margins and improved its operating margin by 4 and 2 percentage points for the three and six-month periods, respectively. Despite increased R&D investments and inflationary pressures on wages, materials, and logistics, Agilent managed its selling, general, and administrative expenses effectively, leading to robust income from operations growth of 25% and 20% year-over-year for the respective periods.
The company also continued its commitment to shareholder returns through consistent dividend payments and substantial share repurchases, with $896 millionc remaining authorization under its 2021 repurchase program as of April 30, 2022. Agilent remains optimistic about its long-term growth prospects across its key end markets, leveraging its diverse portfolio and strategic investments.
02—Key points
Key Highlights
- Total net revenue increased by 5% to $1.61 billion for the three months ended April 30, 2022, and by 7% to $3.28 billion for the six months ended April 30, 2022, compared to the prior year periods.
- Diagnostics and Genomics segment showed strong growth, with revenue increasing by 14% for the quarter and 15% for the six months.
- Net income rose significantly to $274 million for the quarter and $557 million for the six months, up from $216 million and $504 million respectively in the prior year.
- Operating margin improved by 4 percentage points for the quarter and 2 percentage points for the six months, reflecting strong revenue growth and effective expense management.
- The company repurchased approximately $681 million of its common stock in the first six months of fiscal year 2022 under its 2021 repurchase program.
- Despite a temporary revenue impact from a COVID-19 related shutdown in Shanghai, management expects delayed revenue to be recognized in future periods.
- Agilent Technologies declared a quarterly dividend of $0.210 per share, demonstrating a continued commitment to shareholder returns.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2022, Agilent Technologies, Inc. kept $0.17.
- Revenue$1.61B100.0%
- Cost of revenue−$746.0M46.4%
- Gross profit$861.0M53.6%
- Operating costs−$501.0M31.2%
- Operating income$360.0M22.4%
- Interest, other & tax−$86.0M5.4%
- Net income$274.0M17.1%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2022filed May 31, 2022Financial Statements
Q2 FY2022 against Q2 FY2021
| Line item | Q2 FY2022Q2 FY2021 | Change |
|---|---|---|
| Revenue | $1.61B$1.52B | +5.4% |
| Cost of Revenue | $746.00M$708.00M | +5.4% |
| Gross Profit | $861.00M$817.00M | +5.4% |
| R&D Expenses | $115.00M$109.00M | +5.5% |
| SG&A Expenses | $386.00M$420.00M | −8.1% |
| Operating Expenses | $1.25B$1.24B | +0.8% |
| Operating Income | $360.00M$288.00M | +25.0% |
| Interest Expense | $21.00M$20.00M | +5.0% |
| Net Income | $274.00M$216.00M | +26.9% |
| EPS (Basic) | $0.92$0.71 | +29.6% |
| EPS (Diluted) | $0.91$0.70 | +30.0% |
| Shares Outstanding (Basic) | 299.00M304.00M | −1.6% |
| Shares Outstanding (Diluted) | 301.00M307.00M | −2.0% |
05—Questions
Frequently Asked Questions
What was the primary driver of revenue growth for Agilent Technologies during this period?
Revenue growth was driven by increases across all business segments, with notable strength in the Diagnostics and Genomics segment. Growth was observed in the Americas and Europe regions and from key end markets like pharmaceutical, diagnostics and clinical, and chemical and energy. The company also benefited from price increases and increased sales volume, partially offset by unfavorable foreign currency movements and the impact of the COVID-19 lockdown in Shanghai.
How did the COVID-19 lockdown in Shanghai affect Agilent's financial performance?
The mandatory shutdown of Agilent's primary gas chromatography production facility and logistics center in Shanghai due to COVID-19 negatively impacted revenue by approximately 3.5% in the three months ended April 30, 2022. However, management believes this impact is temporary and expects the delayed revenue to be recognized in the second half of fiscal year 2022 and into fiscal year 2023.
What is Agilent's approach to capital allocation, including share repurchases and dividends?
Agilent Technologies continues to prioritize shareholder returns. The company paid quarterly dividends and actively engaged in share repurchases. In the first six months of fiscal year 2022, it repurchased $681 million of common stock under its 2021 repurchase program, which had approximately $896 million remaining authorization as of April 30, 2022. The company also declared a quarterly dividend of $0.210 per share.
What is the outlook for Agilent Technologies given the current economic environment?
Agilent Technologies remains optimistic about its long-term growth opportunities across all its end markets. While acknowledging continued inflationary and logistical pressures, the company is implementing targeted pricing and sourcing strategies to mitigate these impacts. Management expects continued growth in the second half of fiscal year 2022, leveraging its diverse product portfolio and strategic investments.
06—Continue